FDPS and acute lymphoblastic leukemia: We treated the T-ALL cell lines Molt-4 and Jurkat with the isoprenoid biosynthesis inhibitors lovastatin (inhibitor of HMG-CoA reductase), zoledronate (inhibitor of farnesyl diphosphate synthase), and digeranyl bisphosphonate (DGBP) (inhibitor of geranylgeranyl diphosphate synthase)13 (Fig. 1a) to investigate the effect on cell viability.